You just read:

Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health

News provided by

Eiger BioPharmaceuticals, Inc.

Aug 06, 2018, 08:00 ET